TABLE 3.
Subgroup analysis of ARR and ACR of RT combined with ICIs versus ICIs alone in mNSCLC.
| Variable | No. of trials | ARR | No. of trials | ACR | ||||
|---|---|---|---|---|---|---|---|---|
| OR (95% CI) | I2 (%) | p-value | OR (95% CI) | I2 (%) | p-value | |||
| Type | ||||||||
| RCT | 3 | 2.31 (1.19, 4.48) | 11.7 | 0.013 | 3 | 1.85 (1.06, 3.24) | 27.7 | 0.030 |
| NRCT | 1 | 1.55 (0.75, 3.23) | 0.0 | 0.239 | 1 | 1.56 (0.47, 5.12) | 0.0 | 0.467 |
| RT technique | ||||||||
| Hypofractionated RT | 3 | 2.92 (1.40, 6.09) | 19.6 | 0.004 | ||||
| Hyperfractionated RT | 1 | 0.64 (0.10, 4.18) | 0.0 | 0.640 | ||||
| Traditionally fractionated RT | 1 | 1.25 (0.24, 6.54) | 0.0 | 0.792 | ||||
| RT target | ||||||||
| Incranial RT | 0 | Not estimable | NA | NA | 0 | Not estimable | NA | NA |
| Excranial RT | 3 | 2.31 (1.19, 4.48) | 11.7 | 0.013 | 3 | 1.85 (1.06, 3.24) | 27.7 | 0.030 |
| ICI resistance | ||||||||
| Yes | 1 | 0.82 (0.18, 3.71) | 0.0 | 0.792 | 1 | 0.91 (0.33, 2.55) | 0.0 | 0.861 |
| No | 3 | 2.15 (1.29, 3.60) | 0.0 | 0.003 | 3 | 2.22 (1.24, 4.00) | 0.0 | 0.008 |
| PD-L1 level | ||||||||
| ≥50% | 2 | 1.22 (0.23, 6.38) | 0.0 | 0.814 | ||||
| 1%–50% | 2 | 6.77 (0.88, 52.27) | 0.0 | 0.067 | ||||
| <1% | 2 | 2.80 (0.93, 8.46) | 79.8 | 0.067 | ||||
Abbreviations: RT, radiotherapy; ICI, immune checkpoint inhibitor; RCT, randomized controlled trial; NRCT, Non-randomized controlled trial; ARR, abscopal response rate; ACR, abscopal control ratel; mNSCLC, Metastatic non-small cell lung cancer; OR, odds ratio; I2, I-squared for heterogeneity.